Clinical Trials

Carmot is currently conducting a multi-center, randomized, placebo-controlled Phase 2 clinical trial of CT-868 in participants with overweight/obesity and T1D to assess efficacy, safety, tolerability, and pharmacokinetics. https://clinicaltrials.gov/study/NCT06062069

CT-868 is a once-daily subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed as an adjunct to insulin for the treatment of type 1 diabetes (T1D) with overweight or obesity. CT-868 was designed to exhibit signaling bias with no ß-arrestin recruitment to either GLP-1 or GIP receptors, minimizing receptor internalization and consequent desensitization. This signal biased dual GLP-1/GIP receptor agonism is expected to contribute to improved glycemic control, insulin sensitivity, and weight loss.

Carmot is currently conducting a multi-arm, double-blind, placebo-controlled Phase 1b clinical trial of CT-388. The primary endpoint of this trial is to evaluate the safety and tolerability of CT-388 in adult participants with overweight and obesity and in participants with T2D. It is designed to generate robust data to support dose and titration selection for future clinical trials.
https://clinicaltrials.gov/study/NCT04838405

CT-388 is a once-weekly subcutaneous injectable, dual GLP-1/GIP receptor agonist being developed for the treatment of obesity and type 2 diabetes (T2D). CT-388 was designed to have potent activity on both the GLP-1 and GIP receptors but with minimal to no ß-arrestin recruitment on either receptor. This biased signaling significantly minimizes receptor internalization and consequent desensitization, which is expected to lead to prolonged pharmacological activity.

Carmot is currently conducting a double-blind, placebo-controlled Phase 1 clinical trial of CT-996 in participants with overweight or obesity, and in participants with T2D; it is designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of CT-996.
https://clinicaltrials.gov/study/NCT05814107

CT-996 is a once daily oral small molecule agonist of the GLP-1 receptor being developed for the treatment of obesity and type 2 diabetes. Unlike the endogenous GLP-1 hormone, CT-996 was specifically designed to be a biased agonist that activates cAMP signaling with minimal-to-no beta-arrestin recruitment. These signaling properties are expected to lead to strong glycemic control, significant weight loss and good tolerability.